One of the largest pharmaceutical drug distributors covering USA, Canada, Europe.
Showing some bullish signs after coming off a 2 year downtrend, broken out of bearish channel, established priced floor at 135 and moving average cross over.
relatively low PE ratio, beat earnings last 2 quarters with higher earnings projections moving forward according to analysts. Revenue and EPS growth seem to be picking up more as the company matures.
Based off history if momentum picks up could see $300 price in 2 years.
Showing some bullish signs after coming off a 2 year downtrend, broken out of bearish channel, established priced floor at 135 and moving average cross over.
relatively low PE ratio, beat earnings last 2 quarters with higher earnings projections moving forward according to analysts. Revenue and EPS growth seem to be picking up more as the company matures.
Based off history if momentum picks up could see $300 price in 2 years.